US 12,453,724 B2
Ocular implant containing a tyrosine kinase inhibitor
Charles D. Blizzard, Bedford, MA (US); Erica Kahn, Bedford, MA (US); Peter Jarrett, Bedford, MA (US); Rabia Gurses-Ozden, Bedford, MA (US); Rami El-Hayek, Bedford, MA (US); Elizabeth Braun, Bedford, MA (US); Joseph Iacona, Bedford, MA (US); Chintan Patel, Bedford, MA (US); Mark Ransbottom, Bedford, MA (US); Olivia Sherman, Bedford, MA (US); and William Isom, Bedford, WA (US)
Assigned to OCULAR THERAPEUTIX, INC., Bedford, MA (US)
Filed by OCULAR THERAPEUTIX, INC., Bedford, WA (US)
Filed on Apr. 9, 2025, as Appl. No. 19/174,612.
Application 19/174,612 is a continuation of application No. PCT/US2024/023688, filed on Apr. 9, 2024.
Claims priority of provisional application 63/609,334, filed on Dec. 12, 2023.
Claims priority of provisional application 63/546,064, filed on Oct. 27, 2023.
Claims priority of provisional application 63/458,558, filed on Apr. 11, 2023.
Prior Publication US 2025/0235438 A1, Jul. 24, 2025
Int. Cl. A61K 31/4439 (2006.01); A61K 9/00 (2006.01); A61K 47/34 (2017.01)
CPC A61K 31/4439 (2013.01) [A61K 9/0051 (2013.01); A61K 47/34 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method of treating an ocular disease in a patient in need thereof, the treatment comprising administering to the patient's eye by intravitreal injection a sustained release biodegradable ocular implant comprising a hydrogel and axitinib, wherein the implant comprises axitinib polymorph IV in an amount of from about 400 μg to about 500 μg.